The Orthopedic Market experienced healthy growth in H219 fueled by a strong Q319 in the face of difficult comps with the usual fourth-quarter bump due to the seasonality of elective procedures. Looking ahead, several key issues have the potential to impact the US market in 2020. From the economy to taxes, SmartTRAK takes a look at some of the bigger picture issues...
4 min read
4 min read
The US Total Joints Market grew +3.4% in Q319, according to SmartTRAK Financial Dashboard, a sequential improvement over Q2’s 1.8% growth. While the extra selling day in the quarter boosted revenue for most Companies, slightly improved pricing and new product introductions also contributed. Wells Fargo’s Larry Biegelsen estimated recon pricing – based on Stryker, Zimmer Biomet, JNJ/DePuy Synthes, and Smith & Nephew– improved to -1.8% YoY. This sequential improvement in growth and pricing is encouraging especially in the face of a difficult comp from Q318 ...
Among the many topics covered in the complete, comprehensive Q319 Total Joints Market Recap* are:
2 min read
Headed to AAHKS? Our VP of Content Development for Orthopedics, Lisa Mahan, weighs in on what's trending ahead of the meeting.A hot topic at #AAHKS2019 this year will be the move towards outpatient joint replacement surgery with CMS moving to reimburse hospital outpatient total hip replacement and reimbursement of total knee replacement in an ASC setting.
- Outpatient hip and knee replacement surgeries are expected to comprise 57% of all nonfracture knee and hip replacements by the year 2020. ACS Focus
- AAHKS currently does not believe CMS has taken adequate action to address issues arising from
4 min read
At the beginning of the 2019, SmartTRAK looked ahead to the coming year and identified market and technology trends that were likely to shape the Joint Replacement Market landscape in 2019 and beyond. Now that we're approaching the end of the year, here is another look at our predictions.
So what did we see in store for the Total Joints Market? Overall, the theme heading into the new year could be summed up as “Improved Care, Proven Value.” Here are some of the trends we predicted would be worth watching:
5 min read
The WW Market for Foot & Ankle Fixation was up +2.0%, as reported, during Q219, although down sequentially due to tough YoY comps. The US Foot & Ankle Fixation market also experienced a sequential decline in growth. The historically strong segment faced extremely tough YoY comparisons along with no new product launches to spur growth. H119 US growth of...
4 min read
With two earnings seasons of 2019 behind us, US Total Joints Market growth of 1.7% for H119, as modeled by SmartTRAK Financial Dashboard, is trending below SmartTRAK projections of 2.6% growth for FY19. This trend is not surprising considering the heightened seasonality we’ve seen over the last few years in H2 due to high patient deductibles. US Total Joints Market growth strengthened slightly to 1.8% for Q219 compared to 1.6% in Q1 driven by...
4 min read
The US Total Joints Market, which comprises approximately 55% of the global market, experienced stronger growth YoY, up+1.6% for Q119 compared to -0.8% in Q118, according to SmartTRAK Financial Dashboard. Growth also increased sequentially from Q418’s 1.5%.
The market benefited from easier comps against Q118’s nasty flu season which prompted hospitals across the US to postpone surgeries. But SmartTRAK does not believe the bump in growth in the face of easy comps signals a strengthening recon market. Looking back on a 2-yr basis, the market appears to have decelerated 50 bps which suggests an accompanying slow down in the number of procedures taking place early in the year. Wells Fargo’s Larry Biegelsen speculates that...
Among the many topics covered in the Q119 Total Joints Market Recap are:
6 min read
SmartTRAK interviews Arthrosurface CEO Steve Ek about the Company’s newest shoulder system, the OVOMotion, and what differentiates it from other current and emerging shoulder systems
The orthopedic industry has sharpened its focus on value-based care. Health care providers are looking for technologies that maximize care, reduce costs and increase efficiencies, while patients are seeking affordable treatment options that will restore their function and improve their quality of life.
At the 2019 American Academy of Orthopaedic Surgeons (AAOS) Annual Meeting, Arthrosurface CEO Steve Ek, Dr. Greg Nicholson, Rush University Medical Center, and Dr. Anthony Miniaci, Cleveland Clinic, discussed the Company’s newest shoulder implant system, the OVOMotion stemless shoulder, and its value proposition for both health care providers and patients in an interview with SmartTRAK.
(This is Part 2 of SmartTRAK’s interview with Arthrosurface. Be sure to see Part 1 - "Arthrosurface Takes Aim at Patellofemoral Pain" - in which Arthrosurface discusses their new patellofemoral joint implant, the Wave Kahuna.)
4 min read
Arthrosurface hopes to expand the market for joint arthroplasty with a novel patellofemoral arthroplasty implant and five-year data demonstrating long-term clinical benefits for treating patients with patellofemoral pain earlier in the treatment continuum, with evidence suggesting that it halts the progression of osteoarthritis (OA).
Today, many of these patients fall into a treatment gap. As much as 22% of the US population could be suffering from patellofemoral pain, according to a recent analysis of data from 23 studies. PLoS One Many orthopedic surgeons remain unconvinced that surgical management is of long-term benefit. Instead they choose to manage these patients with conservative treatment until they become candidates for joint replacement.
To find out more about the Company’s new patellofemoral arthroplasty implant, the WaveKahuna, and how it can address surgeon concerns about long-term clinical benefits, SmartTRAK interviewed Arthrosurface CEO Steve Ek, and Gregory Nicholson, MD, Rush University Medical Center at the 2019 American Academy of Orthopaedic Surgeon’s (AAOS) Annual Meeting held March 12-16 in Las Vegas, NV.
3 min read
SmartTRAK reports that pricing pressure and a slow down in elective procedures impacted the Extremities market overall, with US Market growth down sequentially from +4.7% seen in Q318 to +3.5% in Q418. The Extremities market no longer seems to be able to fly under the radar and, as healthcare facilities look to maximize reimbursement in all areas, pricing for legacy products are facing discounting. In addition to pricing pressure, economic uncertainty in the US during Q4 led to some healthcare consumers choosing to put off elective procedures...
Among the many topics covered in the Q418/FY18 Extremities Market Recap: